Yahoo Web Search

Search results

1. • 

     US County-Level Study Shows Benefits of PSA Screening

     Medscape· 6 days ago

     A recent analysis found that US counties with higher rates of PSA screening had lower rates of ...

2. • MacroGenics Gets Downgraded Following Disappointing Prostate Cancer Trial Results: 'We Were...

     Benzinga· 5 days ago

     Despite MacroGenics' clinical activity, unexpected adverse events raise concerns. Analysts adjust ratings and price targets.

3. • 

     Fusion Pharmaceuticals doses first subject in prostate cancer trial

     Clinical Trials Arena via Yahoo Finance· 5 days ago

     The open-label, randomised, multicentre AlphaBreak trial aims to determine the safety and efficacy...

4. • 

     MacroGenics reports progress in prostate cancer study By Investing.com

     Investing.com· 6 days ago

     The study investigates vobra duo, an antibody-drug conjugate (ADC), in patients with metastatic...

5. • Astellas Showcases Scientific Advancements Across its Oncology Portfolio at 2024 ASCO Annual Meeting

     WPRI Providence· 2 days ago

     The volume of data being presented by Astellas reinforces its commitment to changing the course of cancer treatment through targeted therapies for hard-to-treat cancers ...

6. • MacroGenics (MGNX) Stock Crashes After Reporting Patient Deaths in TAMARACK Study – Hagens Berman

     Morningstar· 2 days ago

     Hagens Berman urges MacroGenics, Inc. (NASDAQ: MGNX) investors who suffered substantial losses to submit your losses now. The investigation currently focuses on the propriety of MacroGenics’ ...

7. • MacroGenics Provides Update on Corporate Progress, First Quarter 2024 Financial Results and Interim...

     Morningstar· 6 days ago

     Presentation of interim TAMARACK Phase 2 study data: updated safety and preliminary efficacy of vobra duo in mCRPC patientsConference call scheduled for today at 4:30 p.m. ET ROCKVILLE, Md., May 09, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ

8. • New research and treatment advances from Yale Canc | Newswise

     Newswise· 3 days ago

     Nearly 50 presentations by researchers and clinicians from Yale Cancer Center (YCC) at Yale School of Medicine will be among the more than 5,000 abstracts

9. • Telix Pharmaceuticals (OTCMKTS:TLPPF) Shares Up 0.8%

     ETF DAILY NEWS· 6 days ago

     Its lead products include TLX591-CDx for the diagnosis and treatment of metastatic castrate-resistant prostate cancer; TLX250-CDx that ...

10. • 

      After-hours movers: Akamai Technologies, Unity, Macrogenics and more By Investing.com

      Investing.com· 6 days ago

      After-hours movers: Akamai Technologies, Unity, Macrogenics and more